Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1431. doi: 10.3390/cancers11101431.

2.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S.

Target Oncol. 2017 Aug;12(4):525-533. doi: 10.1007/s11523-017-0505-6.

3.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

4.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.

Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.

PMID:
27565910
5.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S.

Br J Cancer. 2015 Dec 22;113(12):1730-4. doi: 10.1038/bjc.2015.401. Epub 2015 Dec 3.

6.

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA.

Br J Cancer. 2009 Oct 20;101(8):1261-8. doi: 10.1038/sj.bjc.6605319. Epub 2009 Sep 22.

7.

Malignant peritoneal mesothelioma: a multicenter study on 81 cases.

Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M.

Ann Oncol. 2010 Feb;21(2):348-53. doi: 10.1093/annonc/mdp307. Epub 2009 Jul 27.

PMID:
19635740
8.

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.

Cartenì G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P; OBI/EPO-ITA-01/1 study group.

Support Care Cancer. 2007 Sep;15(9):1057-66. Epub 2007 Apr 13.

PMID:
17431689
9.

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA.

Ann Oncol. 2007 Mar;18(3):510-7. Epub 2006 Dec 12.

PMID:
17164226
10.

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.

Sartore-Bianchi A, Cerea G, Schiavetto I, Giannetta L, Ricotta R, Maugeri MR, Moroni M, Marrapese G, Siena S.

Ann Oncol. 2006 Mar;17 Suppl 2:ii49-51. Review. No abstract available.

PMID:
16608982
11.

Treatment of metastatic neuroendocrine carcinomas based on WHO classification.

Artale S, Giannetta L, Cerea G, Maggioni D, Pedrazzoli P, Schiavetto I, Napolitano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S.

Anticancer Res. 2005 Nov-Dec;25(6C):4463-9. Erratum in: Anticancer Res. 2006 May-Jun;26(3a):2187. Maggioni, Dario [added].

12.

Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type.

Secondino S, Pedrazzoli P, Giannetta L, Schiavetto I, Vanzulli A, Siena S.

Bone Marrow Transplant. 2004 Nov;34(10):917-8. No abstract available.

13.

Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy.

Siena S, Secondino S, Giannetta L, Carminati O, Pedrazzoli P.

Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S39-47. Review.

PMID:
14563520
15.

Controversies in the management of brain metastases: the role of chemotherapy.

Landonio G, Sartore-Bianchi A, Giannetta L, Renga M, Riva M, Siena S.

Forum (Genova). 2001 Jan-Mar;11(1):59-74. Review.

PMID:
11734865

Supplemental Content

Loading ...
Support Center